Abstract
Design, synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[ a]quinolizines with non-aromatic substituents in the S1 specificity pocket. One representative thereof, carmegliptin ( 8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
